VERVE THERAPEUTICS INC (VERV)
US92539P1012 - Common Stock
| TTM (2024-3-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net Income | -196.83M | -200.07M | -157.39M | -120.31M | -45.70M | |||
| Depreciation Amortization | 5.96M | 5.46M | 2.80M | 1.54M | 1.33M | |||
| Change In Working Capital | 16.97M | 17.70M | 8.38M | -2.91M | 2.64M | |||
| Other non cash items | 30.36M | 27.36M | 23.87M | 43.81M | 6.47M | |||
| OPERATING CASH FLOW | -143.53M | -149.55M | -122.33M | -77.88M | -35.27M | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Capital Expenditure | -6.34M | -9.28M | -13.23M | -4.36M | -3.42M | |||
| Other Investing Activity | -23.00M | 36.97M | -142.72M | -234.74M | -47.70M | |||
| INVESTING CASH FLOW | -29.33M | 27.69M | -155.96M | -239.10M | -51.13M | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Debt Issued/Reduced | N/A | N/A | N/A | 0.00 | 0.00 | |||
| Stock Issued/Repurchased | 233.72M | 213.03M | 329.74M | 379.94M | 92.63M | |||
| Other Financing Activity | N/A | -458.00K | -780.00K | -2.85M | N/A | |||
| FINANCING CASH FLOW | 233.27M | 212.58M | 328.96M | 377.09M | 92.63M | |||
| CHANGE IN CASH | 60.41M | 90.72M | 50.67M | 60.11M | 6.23M | |||
| FREE CASH FLOW | ||||||||
| Operating Cash Flow | -143.53M | -149.55M | -122.33M | -77.88M | -35.27M | |||
| Capital Expenditure | -6.34M | -9.28M | -13.23M | -4.36M | -3.42M | |||
| FREE CASH FLOW | -149.87M | -158.83M | -135.56M | -82.24M | -38.69M | |||
All data in USD